Innate Pharma 주식 가격. IPH - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

2.125

매수가

2.08

매도가

2.13

거래량

1,502,491

2.06 일간 변동폭 2.50

1.332 52주 범위 2.79

market_cap

676.112M

전일 종가

2.09

개장가

2.115

최근 거래 시간

1291

2.125

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

165,118

발행 주식

318,170,508

배당수익률

주가수익률

-89.08

주당순이익(EPS)

-0.02

매출

61.64M

순이익

-7.57M

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.innate-pharma.com

본부

Marseille, Bouches-du-rhone, Fra

설립됨

Innate Pharma is listed in the Biological Pds,ex Diagnstics sector of the 유로넥스트 (Euronext) with ticker IPH. The last closing price for Innate Pharma was 2.09 €. Over the last year, Innate Pharma shares have traded in a share price range of 1.332 € to 2.79 €.

Innate Pharma currently has 318,170,508 shares in issue. The market capitalisation of Innate Pharma is 664.98 € million. Innate Pharma has a price to earnings ratio (PE ratio) of -89.08.

Innate Pharma reçoit le statut de « Breakthrough Therapy » de la FDA pour lacutamab dans le Syndrome de Sézary en rechute ou réfractaire

Le statut est attribué sur la base sur les résultats de la Phase 2 de l’essai TELLOMAK où lacutamab a démontré un niveau d’efficacité et un...

Innate Pharma annonce le traitement du premier patient dans l’essai de Phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées

IPH4502 est un nouveau conjugué anticorps-médicament ciblant Nectine-4 et différencié à base d’exatecan, un inhibiteur de topoisomérase I, comme...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0.175	8.97435897436	1.95	2.5	1.87	134191	2.01748999	DE
4	0.417	24.4145199063	1.708	2.5	1.702	125488	1.91248785	DE
12	0.675	46.5517241379	1.45	2.5	1.332	165118	1.84683838	DE
26	0.129	6.4629258517	1.996	2.5	1.332	110099	1.82625731	DE
52	-0.16	-7.00218818381	2.285	2.79	1.332	86574	1.99586427	DE
156	-1.169	-35.488767456	3.294	3.8	1.332	129715	2.57960458	DE
260	-4.87	-69.62115797	6.995	8.3	1.332	266261	3.94715822	DE

IPH - Frequently Asked Questions (FAQ)

What is the current Innate Pharma share price?

The current share price of Innate Pharma is 2.125 €

How many Innate Pharma shares are in issue?

Innate Pharma has 318,170,508 shares in issue

What is the market cap of Innate Pharma?

The market capitalisation of Innate Pharma is EUR 664.98M

What is the 1 year trading range for Innate Pharma share price?

Innate Pharma has traded in the range of 1.332 € to 2.79 € during the past year

What is the PE ratio of Innate Pharma?

The price to earnings ratio of Innate Pharma is -89.08

What is the cash to sales ratio of Innate Pharma?

The cash to sales ratio of Innate Pharma is 10.94

What is the reporting currency for Innate Pharma?

Innate Pharma reports financial results in EUR

What is the latest annual turnover for Innate Pharma?

The latest annual turnover of Innate Pharma is EUR 61.64M

What is the latest annual profit for Innate Pharma?

The latest annual profit of Innate Pharma is EUR -7.57M

What is the registered address of Innate Pharma?

The registered address for Innate Pharma is 117 AVENUE DE LUMINY, BP 30191, MARSEILLE, BOUCHES-DU-RHONE, 13009

What is the Innate Pharma website address?

The website address for Innate Pharma is www.innate-pharma.com

Which industry sector does Innate Pharma operate in?

Innate Pharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
CYADCelyad Oncology SA	0.77 € (83.55%)	869.82k
YOUNIYounited Financial SA	21.005 € (23.56%)	70
ALNEVNeovacs	0.128 € (20.87%)	718.47k
MLNMAMiguet Et Associes	0.20 € (19.76%)	5.52k
MLGALGaleo Concept	2.50 € (19.05%)	165
BELUBeluga NV	0.438 € (-70.80%)	1k
ARFDSAdeunis DS	0.05 € (-50.00%)	9.2k
ALVGVEOM Group	0.238 € (-24.44%)	332.11k
HDFHydrogene De France	5.99 € (-23.01%)	88.84k
ALVERVergnet	0.0004 € (-20.00%)	77.98M
ATOAtos SE	0.0034 € (17.24%)	4.19B
ALVERVergnet	0.0004 € (-20.00%)	77.98M
BCPBanco Comercial Portugues SA	0.5488 € (1.82%)	59.63M
ALEUPEuroplasma	0.0126 € (-1.56%)	30M
LATLatecoere	0.0113 € (16.49%)	20.1M

shoondale 5 분 전

Review Medsol's Coronacide scam and the bribery felon. I can see why paid pumpers have so much faith.

MGON

zab 5 분 전

https://www.the-express.com/news/world-news/163976/russia-ukraine-demilitarized-peace-talks😂😂

If I was Zelensky I would not want to attend any meeting with Putin, people have a real problem of falling out of windows or having a plane crash. Even worse being poisoned.

MightyX 5 분 전

Shorts must-uh expected 3x current tradeable-OS to cover…they-screwed.

APLD

Monksdream 5 분 전

LUCD, new 52 week high
https://investorshub.advfn.com/uimage/uploads/2025/2/18/fmomlIMG_5325.gif

FOFreddie 5 분 전

Yes - you would think that Thompson would be raising a stink but perhaps the Plaintiffs are waiting for the new Sheriff at the DOJ to come up with a GSE litigation strategy going forward. I know you are a Never Settlement Guy, but I am thinking there may be some method in the madness of the delay

FNMA

Hi_Lo 5 분 전

Hasn't traded in over a week.
That's because it's a scam.

CNNA

I ll be back 5 분 전

This is why I provided the different links.

This could very easily go well beyond diapers as per the initial intent of the product's creation.

You are spot on! Now add in Bob's background and investors can start to connect the dots.

MGON

makinezmoney 5 분 전

$GAMN: AMERICAN FOOD IS GREAT.............

So............. there you go.

Don't even question it............... but what is going on with $HHH

HOLY MAMA

GO $GAMN

GAMN HHH

TheWhigs 5 분 전

How come some of the cheerleaders here are now becoming bearish? 🐻

PSRU

ADTX

They must of wanted out bad to take a loss that large....

ASII

Debunkinator 6 분 전

Now we will have over 100 mil on the ask. Pfffffffffffffffffffffffffffffffffff

ASII

Mr Smith 34 6 분 전

If I understand the pumper's position correctly, Park can't release any top secret information on the price, profit or arrival of gold, chicken pieces and parts, sugar, coal, etc because it would break some imaginary rule, but it's perfectly permissible for him to shout from the roof tops (multipl

SPZI

81vette 6 분 전

Worth 10Xs now,add in 200m paid acquisition,$3+no matter how it’s sliced,so should go quick to $1

GLYC

mckvee 6 분 전

LOL! Yeah LastOne. I'm sorry. I know it's "dollarland" any day now. Really! LOL

ALRTF

dukeb 7 분 전

Let's remember how Dumpty tried to get soldiers to fire bullets at the legs of DC protesters.

make it or break it 7 분 전

FNMA

DGLY

Now that's a company you can get behind bonuses both principles 45,000 a piece for a total of $90,000 which is more than the company did in the last 5 years in business LOL. And they agreed to pay a commission for some group that hasn't generated a dime in sales. Sounds like more OTC garbage but I'l

CLOQ

Mr79 7 분 전

https://media1.giphy.com/media/l1J9PCSuMbUdCu6LS/giphy.gif?cid=6c09b9521afcnqzk6wyhe8kg9ufuou7igyr63ww5syvh3uom&ep=v1_internal_gif_by_id&rid=giphy.gif&ct=g

CNNA

northam43 7 분 전

Report # 10 UPRO Bull Cycle ended today at the close of the 5th hour due to the confirmation of the 60-S-1. This was the 2nd UPRO Bull Cycle of this year, the average is 15.83 UPRO Bull Cycles per year. This cycle lasted 16 trading days, the average is 17.81 trading days. During this cycle there was

Debunkinator 7 분 전

Seems they always wait until the end of the day--Sell what 0.00045 and 0.0005 they can and at the end of the day dump on the 4's. WTH

ASII

dexprs 7 분 전

Bumble options imply 14.0% move in share price post-earnings
THE FLY 3:25 PM ET 2/18/2025
Pre-earnings options volume in Bumble is 25.6x normal with puts leading calls 13:2. Implied volatility suggests the market is anticipating a move near 14.0%, or $1.14, after results are released.

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Innate Pharma (IPH)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Innate Pharma 정보

IPH 최신 뉴스

Innate Pharma reçoit le statut de « Breakthrough Therapy » de la FDA pour lacutamab dans le Syndrome de Sézary en rechute ou réfractaire

Innate Pharma annonce le traitement du premier patient dans l’essai de Phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 31 décembre 2024

Innate Pharma annonce une stratégie de transformation pour accélérer sa croissance

Innate Pharma reçoit le statut de « Breakthrough Therapy » de la FDA pour lacutamab dans le Syndrome de Sézary en rechute ou réfractaire

Innate Pharma annonce le traitement du premier patient dans l’essai de Phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Innate Pharma annonce une stratégie de transformation pour accélérer sa croissance

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaire

IPH - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Innate Pharma (IPH) 시세

Innate Pharma (IPH)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Innate Pharma 정보

IPH 최신 뉴스

Innate Pharma reçoit le statut de « Breakthrough Therapy » de la FDA pour lacutamab dans le Syndrome de Sézary en rechute ou réfractaire

Innate Pharma annonce le traitement du premier patient dans l’essai de Phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 31 décembre 2024

Innate Pharma annonce une stratégie de transformation pour accélérer sa croissance

Innate Pharma reçoit le statut de « Breakthrough Therapy » de la FDA pour lacutamab dans le Syndrome de Sézary en rechute ou réfractaire

Innate Pharma annonce le traitement du premier patient dans l’essai de Phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Innate Pharma annonce une stratégie de transformation pour accélérer sa croissance

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaire

IPH - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거